1
Satellite Symposium: Glycomacropeptide (GMP) and Bone Health (Vitaflo)
30 min
2
Satellite Symposium: Long-Chain Fatty Acid Oxidation Disorders: Evolving Best Practices (Medscape Education Global, Ultragenyx Pharmaceuticals)
30 min
3
Satellite Symposium: Optimizing IEM Care During a Pandemic: A Case-Based Look at UCD Management (Horizon)
30 min
4
Satellite Symposium: Re-defining management of alkaptonuria: Transforming the outlook for patients with the iconic Mendelian disease - a tribute to Archibald Garrod (Sobi)
30 min
5
Satellite Symposium: Shortening the Journey to Fabry Disease Diagnosis: Perspectives from a Patient and Nephrologist (Amicus Therapeutics)
30 min
6
Educational Programme for Adult Metabolic Medicine | Sandra Sirrs & Annalisa Secchi
25 min
7
Update on Complex Lipid Disorders | Fanny Mochel
25 min
8
Key Takeaways and Live Discussion - Voting, Q&A
5 min
9
Introduction | Eva Morava
5 min
10
Clinical, Radiological, and Genetic Characteristics in Patients with ACO2 Gene Defects: An Emerging Neurometabolic Syndrome | Ronen Spiegel
25 min
11
Metabolic Cutis Laxa and The Golgi | Björn Fischer
18 min
12
The International Classification of lnherited Metabolic Disorders, ICIMD | Carlos Ferreira, Shamima Rahman & Johannes Zschocke
18 min
13
News from the FDA: Orphan Drug Development | Patroula Smpokou
18 min
14
In Vivo Gene Therapy for Metabolic Diseases: State of the Art and Future Perspectives | Nicola Brunetti Pierri
18 min
15
Developing Therapy for Ultra-Rare Inherited Metabolic Disease: Lessons from Niemann-Pick Disease Type C | Marc Patterson
18 min
16
Key Takeaways and Live Discussion - Q&A
15 min
17
Introduction | Gajja Salomons
2 min
18
Elucidating the Causes of Metabolic Disorders: The New Veins to Explore | Emile van Schaftingen
43 min
19
An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids | Sacha Ferdinandusse
10 min
20
A novel brain and heart developmental syndrome caused by impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 | Aurora Pujol
10 min
21
A new neurological disease due to PGM2L1 deficiency leads to defective production of glucose-1,6-bisphosphate, but not to a glycosylation defect | Maria Veiga-da-Cunha
10 min
22
GFUS-CDG, a new glycosylation disorder treatable with L-fucose | Saskia Wortmann
10 min
23
Key Takeaways and Live Discussion - Q&A
20 min
24
Satellite Symposium: Distinguishing Pediatric Movement Disorders - Uncovering AADC Deficiency (PTC Therapeutics)
60 min
25
Satellite Symposium: Long-Term Management of Organic Acidemia Patients With CARBAGLU®: The PROTECT Trial Overview & Interim Analysis (Recordati Rare Diseases)
30 min
